GNS chief executive Colin Hill. File photo: Wendy Maeda/Globe Staff.
GNS Healthcare, a Cambridge company that uses Big Data analytics to help life sciences researchers to devise cost-effective personalized treatments for patients with diseases such as cancer, said it has raised $10 million in Series B financing.
Cambia Health Solutions, a Series A investor, was joined in the round by two additional strategic investors: California’s Heritage Provider Network and Mitsui & Co. USA, the company said in a press release.
GNS is deploying enormous computing power to produce a more complete understanding of treatments for rheumatoid arthritis, diabetes, cancers, and other illnesses.
A Globe story from last May noted that GNS is working with the Dana-Farber Cancer Institute and Mount Sinai Medical School to build a computer model of multiple myeloma, so researchers can better understand what works well for patients today, as well as develop more effective treatments for the blood cancer. It is involved in a similar collaboration with Brigham and Women’s Hospital and several other partners to learn more about multiple sclerosis.
Commenting on the $10 million in new financing, GNS chief executive Colin Hill said in a statement: “Our work with leading pharmaceutical companies, health plans, and providers continues to demonstrate the enormous potential that Big Data has to create value in all areas of health care. With the help of Cambia, Heritage, and Mitsui USA, we will continue to provide health care stakeholders with models and products that will improve outcomes while decreasing health care costs.”